Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). (Q36649356)
Jump to navigation
Jump to search
scientific article published on 19 February 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). |
scientific article published on 19 February 2013 |
Statements
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) (English)
Edith A Perez
Michael F Press
Robert B Jenkins
Beiyun Chen
Ivonne Villalobos
Soonmyung Paik
Anne E Wiktor
Reid Meyer
Melanie Finnigan
Joanne Zujewski
Mona Shing
Howard M Stern
Monica M Reinholz
Dennis J Slamon
19 February 2013
1 February 2013
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference